Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Obinutuzumab in Chinese Patients With Indolent Non-Hodgkin's B-cell Lymphoma in the Real-World.

NCT05968001 is registered in ClinicalTrials.gov with Affiliated Hospital of Nantong University as lead sponsor.

NCT NCT05968001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05968001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Obinutuzumab in Chinese Patients With Indolent Non-Hodgkin's B-cell Lymphoma in the Real-World.
Lead sponsor
Affiliated Hospital of Nantong University
Phase
Observational
Overall status
Unknown status
Start date
July 20, 2023
Completion date
July 20, 2026
Enrollment
400 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

lymphomas non-hodgkin's b-cell